Service expected to help companies discover partners in funding.
Pharma Targeting, a pharmaceutical market intelligence and data company, has announced the launch of ‘Partner Identifier’, an initiative designed to help pharma and biotech companies find the partners they need to get funded, noticed, and faster to market. According to the organization, the technology uses data-driven intelligence to help customers identify and engage with the right partner for licensing, in-licensing, funding, distribution, and other business needs.
“The Partner Identifier was born out of a client need, adjusted, and implemented to help them to identify and engage with the right partner, at the right time, with an aligning strategy and the necessary funds in place,” says Anil Kumar, founder, Pharma Targeting. “We do the challenging work of finding and contacting our clients’ potential partners, so that all they have to do is make connections and build relationships. The ultimate goal is helping our clients to achieve meaningful collaboration and partnership, and get their products to market quicker.”
Reference:
Pharma Targeting Launch ‘Partner Identifier’ to Intelligently Connect the Dots between Data and Business Opportunity for Pharma Clients. (2023, July 6).
Beyond the Birthrate: The Societal Costs of Maternal Mortality
September 6th 2024Head of Medical Affairs and Outcomes Research at Organon, Charlotte Owens, MD, FACOG, discusses the most critical changes needed to close the gaps in R&D for maternal health solutions and how feasible they are to make.
Efsitora Demonstrates Non-Inferiority vs. Insulin Glargine, Degludec for Type 2 Diabetes
September 5th 2024Results from the QWINT-1 and QWINT-3 trials found that insulin-naïve patients achieved similar reductions in A1C levels using once-weekly efsitora compared to daily insulin glargine and degludec.